WO2015023858A3 - Uses of phospholipid conjugates of synthetic tlr7 agonists - Google Patents
Uses of phospholipid conjugates of synthetic tlr7 agonists Download PDFInfo
- Publication number
- WO2015023858A3 WO2015023858A3 PCT/US2014/051090 US2014051090W WO2015023858A3 WO 2015023858 A3 WO2015023858 A3 WO 2015023858A3 US 2014051090 W US2014051090 W US 2014051090W WO 2015023858 A3 WO2015023858 A3 WO 2015023858A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phospholipid
- tlr7 agonists
- phospholipid conjugates
- agonists
- synthetic tlr7
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides uses for phospholipid conjugates of TLR agonists as enhancers of an innate immune response. Specifically, purine derivatives which are conjugated to a phospholipid or an analog thereof are disclosed as having activity as TLR7 agonists, capable of inducing an innate immune response upon administration in an effective amount to a subject. The phospholipid moiety of the TLR7 agonist contains one or more alkyl ether or ester moieties.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14835923.5A EP3033089A2 (en) | 2013-08-16 | 2014-08-14 | Uses of phospholipid conjugates of synthetic tlr7 agonists |
US14/912,043 US20160199499A1 (en) | 2013-08-16 | 2014-08-14 | Uses of phospholipid conjugates of synthetic tlr7 agonists |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361866700P | 2013-08-16 | 2013-08-16 | |
US61/866,700 | 2013-08-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2015023858A2 WO2015023858A2 (en) | 2015-02-19 |
WO2015023858A3 true WO2015023858A3 (en) | 2015-11-26 |
Family
ID=52468810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/051090 WO2015023858A2 (en) | 2013-08-16 | 2014-08-14 | Uses of phospholipid conjugates of synthetic tlr7 agonists |
Country Status (3)
Country | Link |
---|---|
US (1) | US20160199499A1 (en) |
EP (1) | EP3033089A2 (en) |
WO (1) | WO2015023858A2 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11697851B2 (en) | 2016-05-24 | 2023-07-11 | The Regents Of The University Of California | Early ovarian cancer detection diagnostic test based on mRNA isoforms |
US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
WO2019209811A1 (en) | 2018-04-24 | 2019-10-31 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (tlr7) agonists |
US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
CN115210236A (en) | 2020-01-27 | 2022-10-18 | 百时美施贵宝公司 | 1H-pyrazolo [4,3-d ] pyrimidine compounds as Toll-like receptor 7 (TLR 7) agonists |
KR20220132593A (en) | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists |
EP4097108A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
CN115210235A (en) | 2020-01-27 | 2022-10-18 | 百时美施贵宝公司 | 1H-pyrazolo [4,3-d ] pyrimidine compounds as Toll-like receptor 7 (TLR 7) agonists |
EP4097101A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
JP2023512207A (en) | 2020-01-27 | 2023-03-24 | ブリストル-マイヤーズ スクイブ カンパニー | 1H-pyrazolo[4,3-d]pyrimidine compounds as Toll-like receptor 7 (TLR7) agonists |
US20230127326A1 (en) | 2020-01-27 | 2023-04-27 | Bristol-Myers Squibb Company | C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
CN115643805A (en) | 2020-01-27 | 2023-01-24 | 百时美施贵宝公司 | 1H-pyrazolo [4,3-d ] pyrimidine compounds as Toll-like receptor 7 (TLR 7) agonists |
WO2021154664A1 (en) | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011139348A2 (en) * | 2010-04-30 | 2011-11-10 | The Regents Of The University Of California | Uses of phospholipid conjugates of synthetic tlr7 agonists |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2510946T3 (en) * | 2007-02-07 | 2015-11-02 | Univ California | Conjugates of synthetic fluorescent agonists and their applications |
-
2014
- 2014-08-14 EP EP14835923.5A patent/EP3033089A2/en not_active Withdrawn
- 2014-08-14 US US14/912,043 patent/US20160199499A1/en not_active Abandoned
- 2014-08-14 WO PCT/US2014/051090 patent/WO2015023858A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011139348A2 (en) * | 2010-04-30 | 2011-11-10 | The Regents Of The University Of California | Uses of phospholipid conjugates of synthetic tlr7 agonists |
Also Published As
Publication number | Publication date |
---|---|
US20160199499A1 (en) | 2016-07-14 |
WO2015023858A2 (en) | 2015-02-19 |
EP3033089A2 (en) | 2016-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015023858A3 (en) | Uses of phospholipid conjugates of synthetic tlr7 agonists | |
MY174813A (en) | Cytotoxic and anti-mitotic compounds, and methods of using the same | |
MX2020000333A (en) | Anti-egfr antibody drug conjugate formulations. | |
IL292062A (en) | New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds | |
EP3040072A4 (en) | Pharmaceutical composition having pyrimidine compound as active ingredient | |
CL2015002330A1 (en) | Innovative insulin analogue and its use. | |
MX2015008627A (en) | Boronic acid derivatives and therapeutic uses thereof. | |
PT2972360T (en) | Synergistic enhancement of the delivery of nucleic acids via blended formulations | |
EP3082797A4 (en) | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | |
BR112016008736A2 (en) | Stable formulation of insulin glulisine | |
MX2015002482A (en) | Immunogenic composition. | |
IL231421A (en) | Lupane and its analogs substituted in position 3ß with carboxyalkylcarbonyloxy and in position 17 with (substituted alkyl)amino, as well as anti-hiv pharmaceutical compositions comprising them | |
BR112015022587A2 (en) | chimeric cytokine formulations for ocular delivery | |
MX2016001422A (en) | Pharmaceutical compositions of fingolimod. | |
MX363530B (en) | Tricyclic benzoxaborole compound, preparation method therefor, and use thereof. | |
EP3090749A4 (en) | Nutrient composition having lipid metabolism-improving action | |
AU2014271207A1 (en) | Targeted delivery of drugs to the myometrium | |
EP2999461A4 (en) | Targeted delivery of drugs to the myometrium | |
IL253105A0 (en) | Synthetic apelin fatty acid conjugates with improved half-life | |
EP3036260A4 (en) | Bruton's tyrosine kinase as anti-cancer drug target | |
EP3040337A4 (en) | 2, 6-di-nitrogen-containing substituted purine derivative, and preparation method, pharmaceutical composition and use thereof | |
BR112015023730A2 (en) | use of sedoeptulose as a nutritional supplement | |
MY180228A (en) | Mucosal immunostimulator | |
EP3305267A4 (en) | Fifth generation fu's needle | |
BR112016007617A2 (en) | tenofovir disoproxyl dihydrogen phosphate, method for preparing tenofovir disoproxyl dihydrogen phosphate and pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14835923 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2014835923 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014835923 Country of ref document: EP |